
Release date: 2026-03-04 15:18:04 Article From: Lucius Laos Recommended: 8
Stiripentol is an adjuvant drug commonly used for drug-resistant epilepsy (such as Dravet syndrome). Its common side effects include drowsiness, loss of appetite, fatigue, weight changes, and gastrointestinal discomfort. In severe cases, it may cause liver dysfunction, hematological effects, or allergic reactions. Liver function and blood routine should be strictly monitored during treatment, and the dosage should be adjusted in accordance with medical advice.
Neurological reactions: Drowsiness, dizziness, decreased attention, etc., which may affect daily activities.
Gastrointestinal discomfort: Nausea, vomiting, diarrhea, or constipation. It is recommended to take it with meals to reduce irritation.
Metabolic effects: Weight loss or loss of appetite. Nutritional status should be monitored, and a high-calorie diet should be supplemented if necessary.
Liver dysfunction: Manifested as jaundice, abdominal pain, and dark urine. Liver enzyme levels should be regularly monitored.
Hematological disorders: Such as decreased white blood cells or platelets, which may increase the risk of infection or bleeding.
Allergic reactions: Rash, difficulty breathing, facial swelling. The drug should be discontinued immediately and emergency treatment provided.
Children: May affect growth and development. Height, weight, and cognitive function should be regularly evaluated.
Patients with hepatic and renal insufficiency: Use with caution, and adjust the dosage according to test results.
Strictly follow the doctor’s instructions. Do not increase, decrease the dosage, or discontinue the drug without authorization.
Avoid concurrent use with alcohol or other central nervous system depressants, which may increase the risk of drowsiness.
Recheck liver function and blood routine every 2–4 weeks at the initial stage of treatment, and extend the interval to 3–6 months after stabilization.
If persistent vomiting, abnormal bleeding, severe rash, or confusion occurs during treatment, discontinue the drug immediately and seek medical attention.
Lucius Pharmaceuticals Stiripentol is a prescription drug. Its use should be individualized, and a regimen should be formulated by a professional physician after weighing the efficacy and risks.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1492025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3922024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1442025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1652025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1482025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1722025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1562025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1542025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: